Navigation Links
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
Date:10/21/2013

numet XR in the United States and other licensed territories through the expiration of the licensed patents pursuant to Depomed's license arrangement with Merck.

PDL also acquired certain rights to royalties and milestones on products currently in development by Boehringer Ingelheim and Janssen Pharmaceutica. Boehringer Ingelheim has worldwide rights to Depomed's Acuform® delivery technology for the development and commercialization of certain fixed dose combination products which include extended release metformin and proprietary Boehringer Ingelheim compounds currently in development for type 2 diabetes. Subject to clinical development and product approval, PDL may receive Depomed's milestone payments based on regulatory filings and approval events, as well as royalties on worldwide net sales of products sold by Boehringer Ingelheim. Janssen Pharmaceutica has worldwide rights to Acuform delivery technology for the development and commercialization of a fixed dose combination formulation of Janssen's type 2 diabetes product candidate, Invokana (canagliflozin), a Sodium Glucose Transport 2 (SGLT2) inhibitor, and extended-release metformin. Subject to clinical development and product approval, PDL may receive Depomed's milestone payments and royalties on worldwide net sales of products sold by Janssen under the Depomed license.

About PDL BioPharma

PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue. PDL is currently focused on intellectual property asset management, investing in new income generating assets, and
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PDL BioPharma Provides $60 Million in Financing to LENSAR
2. Global Biopharma Mergers & Acquisition and Deal Making Report 2013: Understanding the Latest Trends to Optimize Future Strategy
3. PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference
4. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
5. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
6. New HAE Drug Candidate from Dyax Produced by Laureate Biopharma
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
9. PDL BioPharma Announces Second Quarter 2013 Financial Results
10. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
11. Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
(Date:9/18/2014)... 18, 2014 After 6 months of ... finally here - the new programme for the next Cool ... of our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA ... programme that is broad and yet specific, focused and yet ...
(Date:9/18/2014)... 18, 2014   Regulus Therapeutics Inc . ... leading the discovery and development of innovative medicines ... ATHENA natural history of disease study in patients ... with no approved therapy. The ATHENA study is ... function markers such as Glomerular Filtration Rate ("GFR"), ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... March 31, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... is initiating launch activities of Nulecit™ (sodium ferric ... of GeneraMedix Inc.,s, Abbreviated New Drug Application (ANDA). ... alternative to Sanofi-Aventis, Ferrlecit ® .  In July ...
... DIEGO, March 31, 2011 OncoSec Medical Inc. (OTC BB: ... tumor cancers, announced today that it has raised more than ... to three institutional investors. OncoSec issued 1,456,000 units at a ... Each unit consisted of one share of common stock and ...
Cached Medicine Technology:Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 3Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 4OncoSec Medical Closes $1.1M Financing 2
(Date:9/18/2014)... Springs, FL (PRWEB) September 18, 2014 It ... and run, sprint or walk for healthier and happier kids. ... support and participate in the 4th Annual Miami Children’s Hospital ... Wheels. http://www.hyundaihopeonwheels.org , The 5K will ... finishing location will be outside of Coral Gables City Hall ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... . Two ... ,International Space Station Research Competition, with their project ,Egypt ... will see the International Space Station crew perform experiments ... proteins of the hepatitis C virus under microgravity conditions. ... Station is scheduled to lift off from Cape Canaveral ...
(Date:9/18/2014)... 18, 2014 PlatinumCode, a leading ... collection products for the healthcare industry, announced earlier ... five percent of their profits of the sale ... In making the announcement, PlatinumCode has launched various ... providing clinical and hospital labs with their popular ...
(Date:9/18/2014)... 2014 T-System Inc. today announced ... documentation system — EV™ for physicians ... assessing several best-of-breed solutions, Holyoke chose T-System’s solution ... physician productivity and reimbursement, but also its ability ... still be used to capture emergency department, (ED) ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Hepatitis C virus proteins in space 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2
... active participation in their communities has led researchers to define this ... now be considered a distinct retirement role, according to an article ... (Volume 48, Number 3). , The authors identify civic ... one day per week that directly impact the local community. ...
... 6 hours for participants in phase II trial ... gout drug called pegloticase lowered levels of uric acid ... hours in most patients. , That,s the conclusion of ... and Savient Pharmaceuticals, the company that,s developing the drug. ...
... Ill., Sept. 3 Z Trim Holdings,Inc. (Amex: ... 2, 2008, the Company,entered into private placement subscription ... of convertible notes and warrants, for an,aggregate offering ... a,"Unit" and collectively, the "Units") consists of a ...
... 28,000 ratings and comments are overwhelmingly positive, ... of,Regence members would recommend their doctor to others, ... member Web site -- myRegence.com. A,"Member Feedback" feature ... on their experiences with individual providers, including,physicians, dentists, ...
... (doi:10.1016/j.clim.2008.06.009) published in Clinical Immunology, the official ... new method enabling the detection of multiple parameters of ... specific blood cells from an individual with type 1 ... play in the development of the disease and during ...
... on earnings and productivity for healthcare professionals in the United States, ... decrease in patient loads. , ... New York, NY ... focusing on earnings and productivity for physicians in America features some ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: